

Global Short-acting EPO Drugs Market Growth 2023-2029

<https://marketpublishers.com/r/GE17519CCE93EN.html>

Date: October 2023

Pages: 104

Price: US\$ 3,660.00 (Single User License)

ID: GE17519CCE93EN

Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

According to our LPI (LP Information) latest study, the global Short-acting EPO Drugs market size was valued at US\$ 8980.3 million in 2022. With growing demand in downstream market, the Short-acting EPO Drugs is forecast to a readjusted size of US\$ 13890 million by 2029 with a CAGR of 6.4% during review period.

The research report highlights the growth potential of the global Short-acting EPO Drugs market. Short-acting EPO Drugs are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Short-acting EPO Drugs. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Short-acting EPO Drugs market.

Erythropoietin is produced by interstitial fibroblasts in the kidney in close association with peritubular capillary and proximal convoluted tubule. It is also produced in perisinusoidal cells in the liver. While liver production predominates in the fetal and perinatal period, renal production is predominant during adulthood.

Short-acting EPO drugs have a wide range of applications in the market, primarily used for treating anemia-related conditions such as anemia associated with chronic kidney disease and in the supportive treatment of leukemia patients. The market size is substantial and continues to grow, particularly in Asian and European regions. Sales have been on the rise, reflecting increasing patient demand and benefiting from ongoing advancements in medical technology. In the future, short-acting EPO drugs are poised

for further development, potentially encompassing the treatment of more anemia-related conditions and expanding their market share through innovative therapies and market expansion efforts.

Key Features:

The report on Short-acting EPO Drugs market reflects various aspects and provide valuable insights into the industry.

Market Size and Growth: The research report provide an overview of the current size and growth of the Short-acting EPO Drugs market. It may include historical data, market segmentation by Type (e.g., Epoetin-alfa, Epoetin-beta), and regional breakdowns.

Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Short-acting EPO Drugs market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.

Competitive Landscape: The research report provides analysis of the competitive landscape within the Short-acting EPO Drugs market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.

Technological Developments: The research report can delve into the latest technological developments in the Short-acting EPO Drugs industry. This include advancements in Short-acting EPO Drugs technology, Short-acting EPO Drugs new entrants, Short-acting EPO Drugs new investment, and other innovations that are shaping the future of Short-acting EPO Drugs.

Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Short-acting EPO Drugs market. It includes factors influencing customer ' purchasing decisions, preferences for Short-acting EPO Drugs product.

Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Short-acting EPO Drugs market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Short-acting EPO Drugs market. The report also

evaluates the effectiveness of these policies in driving market growth.

Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Short-acting EPO Drugs market.

Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Short-acting EPO Drugs industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.

Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Short-acting EPO Drugs market.

Market Segmentation:

Short-acting EPO Drugs market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.

Segmentation by type

Epoetin-alfa

Epoetin-beta

Darbepoetin-alfa

Others

Segmentation by application

Anemia

Kidney Disorders

Others

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

Amgen

Johnson & Johnson

Roche

Kyowa Kirin

LG Chem

Daewoong Pharmaceutical

Wockhardt

CJ Healthcare

3SBio

Kexing Biopharm

Harbin Pharmaceutical Group

Beijing Four Rings Bio-Pharmaceutical

Key Questions Addressed in this Report

What is the 10-year outlook for the global Short-acting EPO Drugs market?

What factors are driving Short-acting EPO Drugs market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Short-acting EPO Drugs market opportunities vary by end market size?

How does Short-acting EPO Drugs break out type, application?

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview

- 2.1.1 Global Short-acting EPO Drugs Annual Sales 2018-2029
- 2.1.2 World Current & Future Analysis for Short-acting EPO Drugs by Geographic Region, 2018, 2022 & 2029
- 2.1.3 World Current & Future Analysis for Short-acting EPO Drugs by Country/Region, 2018, 2022 & 2029

2.2 Short-acting EPO Drugs Segment by Type

- 2.2.1 Epoetin-alfa
- 2.2.2 Epoetin-beta
- 2.2.3 Darbepoetin-alfa
- 2.2.4 Others

2.3 Short-acting EPO Drugs Sales by Type

- 2.3.1 Global Short-acting EPO Drugs Sales Market Share by Type (2018-2023)
- 2.3.2 Global Short-acting EPO Drugs Revenue and Market Share by Type (2018-2023)
- 2.3.3 Global Short-acting EPO Drugs Sale Price by Type (2018-2023)

2.4 Short-acting EPO Drugs Segment by Application

- 2.4.1 Anemia
- 2.4.2 Kidney Disorders
- 2.4.3 Others

2.5 Short-acting EPO Drugs Sales by Application

- 2.5.1 Global Short-acting EPO Drugs Sale Market Share by Application (2018-2023)
- 2.5.2 Global Short-acting EPO Drugs Revenue and Market Share by Application (2018-2023)

2.5.3 Global Short-acting EPO Drugs Sale Price by Application (2018-2023)

3 GLOBAL SHORT-ACTING EPO DRUGS BY COMPANY

3.1 Global Short-acting EPO Drugs Breakdown Data by Company

3.1.1 Global Short-acting EPO Drugs Annual Sales by Company (2018-2023)

3.1.2 Global Short-acting EPO Drugs Sales Market Share by Company (2018-2023)

3.2 Global Short-acting EPO Drugs Annual Revenue by Company (2018-2023)

3.2.1 Global Short-acting EPO Drugs Revenue by Company (2018-2023)

3.2.2 Global Short-acting EPO Drugs Revenue Market Share by Company (2018-2023)

3.3 Global Short-acting EPO Drugs Sale Price by Company

3.4 Key Manufacturers Short-acting EPO Drugs Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers Short-acting EPO Drugs Product Location Distribution

3.4.2 Players Short-acting EPO Drugs Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)

3.6 New Products and Potential Entrants

3.7 Mergers & Acquisitions, Expansion

4 WORLD HISTORIC REVIEW FOR SHORT-ACTING EPO DRUGS BY GEOGRAPHIC REGION

4.1 World Historic Short-acting EPO Drugs Market Size by Geographic Region (2018-2023)

4.1.1 Global Short-acting EPO Drugs Annual Sales by Geographic Region (2018-2023)

4.1.2 Global Short-acting EPO Drugs Annual Revenue by Geographic Region (2018-2023)

4.2 World Historic Short-acting EPO Drugs Market Size by Country/Region (2018-2023)

4.2.1 Global Short-acting EPO Drugs Annual Sales by Country/Region (2018-2023)

4.2.2 Global Short-acting EPO Drugs Annual Revenue by Country/Region (2018-2023)

4.3 Americas Short-acting EPO Drugs Sales Growth

4.4 APAC Short-acting EPO Drugs Sales Growth

4.5 Europe Short-acting EPO Drugs Sales Growth

4.6 Middle East & Africa Short-acting EPO Drugs Sales Growth

5 AMERICAS

5.1 Americas Short-acting EPO Drugs Sales by Country

5.1.1 Americas Short-acting EPO Drugs Sales by Country (2018-2023)

5.1.2 Americas Short-acting EPO Drugs Revenue by Country (2018-2023)

5.2 Americas Short-acting EPO Drugs Sales by Type

5.3 Americas Short-acting EPO Drugs Sales by Application

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Short-acting EPO Drugs Sales by Region

6.1.1 APAC Short-acting EPO Drugs Sales by Region (2018-2023)

6.1.2 APAC Short-acting EPO Drugs Revenue by Region (2018-2023)

6.2 APAC Short-acting EPO Drugs Sales by Type

6.3 APAC Short-acting EPO Drugs Sales by Application

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

6.10 China Taiwan

7 EUROPE

7.1 Europe Short-acting EPO Drugs by Country

7.1.1 Europe Short-acting EPO Drugs Sales by Country (2018-2023)

7.1.2 Europe Short-acting EPO Drugs Revenue by Country (2018-2023)

7.2 Europe Short-acting EPO Drugs Sales by Type

7.3 Europe Short-acting EPO Drugs Sales by Application

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Short-acting EPO Drugs by Country

8.1.1 Middle East & Africa Short-acting EPO Drugs Sales by Country (2018-2023)

8.1.2 Middle East & Africa Short-acting EPO Drugs Revenue by Country (2018-2023)

8.2 Middle East & Africa Short-acting EPO Drugs Sales by Type

8.3 Middle East & Africa Short-acting EPO Drugs Sales by Application

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers

10.2 Manufacturing Cost Structure Analysis of Short-acting EPO Drugs

10.3 Manufacturing Process Analysis of Short-acting EPO Drugs

10.4 Industry Chain Structure of Short-acting EPO Drugs

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel

11.1.1 Direct Channels

11.1.2 Indirect Channels

11.2 Short-acting EPO Drugs Distributors

11.3 Short-acting EPO Drugs Customer

12 WORLD FORECAST REVIEW FOR SHORT-ACTING EPO DRUGS BY GEOGRAPHIC REGION

12.1 Global Short-acting EPO Drugs Market Size Forecast by Region

- 12.1.1 Global Short-acting EPO Drugs Forecast by Region (2024-2029)
- 12.1.2 Global Short-acting EPO Drugs Annual Revenue Forecast by Region (2024-2029)
- 12.2 Americas Forecast by Country
- 12.3 APAC Forecast by Region
- 12.4 Europe Forecast by Country
- 12.5 Middle East & Africa Forecast by Country
- 12.6 Global Short-acting EPO Drugs Forecast by Type
- 12.7 Global Short-acting EPO Drugs Forecast by Application

13 KEY PLAYERS ANALYSIS

13.1 Amgen

- 13.1.1 Amgen Company Information
- 13.1.2 Amgen Short-acting EPO Drugs Product Portfolios and Specifications
- 13.1.3 Amgen Short-acting EPO Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
- 13.1.4 Amgen Main Business Overview
- 13.1.5 Amgen Latest Developments

13.2 Johnson & Johnson

- 13.2.1 Johnson & Johnson Company Information
- 13.2.2 Johnson & Johnson Short-acting EPO Drugs Product Portfolios and Specifications
- 13.2.3 Johnson & Johnson Short-acting EPO Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
- 13.2.4 Johnson & Johnson Main Business Overview
- 13.2.5 Johnson & Johnson Latest Developments

13.3 Roche

- 13.3.1 Roche Company Information
- 13.3.2 Roche Short-acting EPO Drugs Product Portfolios and Specifications
- 13.3.3 Roche Short-acting EPO Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
- 13.3.4 Roche Main Business Overview
- 13.3.5 Roche Latest Developments

13.4 Kyowa Kirin

- 13.4.1 Kyowa Kirin Company Information
- 13.4.2 Kyowa Kirin Short-acting EPO Drugs Product Portfolios and Specifications
- 13.4.3 Kyowa Kirin Short-acting EPO Drugs Sales, Revenue, Price and Gross Margin (2018-2023)

- 13.4.4 Kyowa Kirin Main Business Overview
- 13.4.5 Kyowa Kirin Latest Developments
- 13.5 LG Chem
 - 13.5.1 LG Chem Company Information
 - 13.5.2 LG Chem Short-acting EPO Drugs Product Portfolios and Specifications
 - 13.5.3 LG Chem Short-acting EPO Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.5.4 LG Chem Main Business Overview
 - 13.5.5 LG Chem Latest Developments
- 13.6 Daewoong Pharmaceutical
 - 13.6.1 Daewoong Pharmaceutical Company Information
 - 13.6.2 Daewoong Pharmaceutical Short-acting EPO Drugs Product Portfolios and Specifications
 - 13.6.3 Daewoong Pharmaceutical Short-acting EPO Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.6.4 Daewoong Pharmaceutical Main Business Overview
 - 13.6.5 Daewoong Pharmaceutical Latest Developments
- 13.7 Wockhardt
 - 13.7.1 Wockhardt Company Information
 - 13.7.2 Wockhardt Short-acting EPO Drugs Product Portfolios and Specifications
 - 13.7.3 Wockhardt Short-acting EPO Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.7.4 Wockhardt Main Business Overview
 - 13.7.5 Wockhardt Latest Developments
- 13.8 CJ Healthcare
 - 13.8.1 CJ Healthcare Company Information
 - 13.8.2 CJ Healthcare Short-acting EPO Drugs Product Portfolios and Specifications
 - 13.8.3 CJ Healthcare Short-acting EPO Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.8.4 CJ Healthcare Main Business Overview
 - 13.8.5 CJ Healthcare Latest Developments
- 13.9 3SBio
 - 13.9.1 3SBio Company Information
 - 13.9.2 3SBio Short-acting EPO Drugs Product Portfolios and Specifications
 - 13.9.3 3SBio Short-acting EPO Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.9.4 3SBio Main Business Overview
 - 13.9.5 3SBio Latest Developments
- 13.10 Kexing Biopharm

- 13.10.1 Kexing Biopharm Company Information
- 13.10.2 Kexing Biopharm Short-acting EPO Drugs Product Portfolios and Specifications
- 13.10.3 Kexing Biopharm Short-acting EPO Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
- 13.10.4 Kexing Biopharm Main Business Overview
- 13.10.5 Kexing Biopharm Latest Developments
- 13.11 Harbin Pharmaceutical Group
 - 13.11.1 Harbin Pharmaceutical Group Company Information
 - 13.11.2 Harbin Pharmaceutical Group Short-acting EPO Drugs Product Portfolios and Specifications
 - 13.11.3 Harbin Pharmaceutical Group Short-acting EPO Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.11.4 Harbin Pharmaceutical Group Main Business Overview
 - 13.11.5 Harbin Pharmaceutical Group Latest Developments
- 13.12 Beijing Four Rings Bio-Pharmaceutical
 - 13.12.1 Beijing Four Rings Bio-Pharmaceutical Company Information
 - 13.12.2 Beijing Four Rings Bio-Pharmaceutical Short-acting EPO Drugs Product Portfolios and Specifications
 - 13.12.3 Beijing Four Rings Bio-Pharmaceutical Short-acting EPO Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.12.4 Beijing Four Rings Bio-Pharmaceutical Main Business Overview
 - 13.12.5 Beijing Four Rings Bio-Pharmaceutical Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Short-acting EPO Drugs Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & (\$ millions)

Table 2. Short-acting EPO Drugs Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & (\$ millions)

Table 3. Major Players of Epoetin-alfa

Table 4. Major Players of Epoetin-beta

Table 5. Major Players of Darbepoetin-alfa

Table 6. Major Players of Others

Table 7. Global Short-acting EPO Drugs Sales by Type (2018-2023) & (K Units)

Table 8. Global Short-acting EPO Drugs Sales Market Share by Type (2018-2023)

Table 9. Global Short-acting EPO Drugs Revenue by Type (2018-2023) & (\$ million)

Table 10. Global Short-acting EPO Drugs Revenue Market Share by Type (2018-2023)

Table 11. Global Short-acting EPO Drugs Sale Price by Type (2018-2023) & (US\$/Unit)

Table 12. Global Short-acting EPO Drugs Sales by Application (2018-2023) & (K Units)

Table 13. Global Short-acting EPO Drugs Sales Market Share by Application (2018-2023)

Table 14. Global Short-acting EPO Drugs Revenue by Application (2018-2023)

Table 15. Global Short-acting EPO Drugs Revenue Market Share by Application (2018-2023)

Table 16. Global Short-acting EPO Drugs Sale Price by Application (2018-2023) & (US\$/Unit)

Table 17. Global Short-acting EPO Drugs Sales by Company (2018-2023) & (K Units)

Table 18. Global Short-acting EPO Drugs Sales Market Share by Company (2018-2023)

Table 19. Global Short-acting EPO Drugs Revenue by Company (2018-2023) (\$ Millions)

Table 20. Global Short-acting EPO Drugs Revenue Market Share by Company (2018-2023)

Table 21. Global Short-acting EPO Drugs Sale Price by Company (2018-2023) & (US\$/Unit)

Table 22. Key Manufacturers Short-acting EPO Drugs Producing Area Distribution and Sales Area

Table 23. Players Short-acting EPO Drugs Products Offered

Table 24. Short-acting EPO Drugs Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)

Table 25. New Products and Potential Entrants

Table 26. Mergers & Acquisitions, Expansion

Table 27. Global Short-acting EPO Drugs Sales by Geographic Region (2018-2023) & (K Units)

Table 28. Global Short-acting EPO Drugs Sales Market Share Geographic Region (2018-2023)

Table 29. Global Short-acting EPO Drugs Revenue by Geographic Region (2018-2023) & (\$ millions)

Table 30. Global Short-acting EPO Drugs Revenue Market Share by Geographic Region (2018-2023)

Table 31. Global Short-acting EPO Drugs Sales by Country/Region (2018-2023) & (K Units)

Table 32. Global Short-acting EPO Drugs Sales Market Share by Country/Region (2018-2023)

Table 33. Global Short-acting EPO Drugs Revenue by Country/Region (2018-2023) & (\$ millions)

Table 34. Global Short-acting EPO Drugs Revenue Market Share by Country/Region (2018-2023)

Table 35. Americas Short-acting EPO Drugs Sales by Country (2018-2023) & (K Units)

Table 36. Americas Short-acting EPO Drugs Sales Market Share by Country (2018-2023)

Table 37. Americas Short-acting EPO Drugs Revenue by Country (2018-2023) & (\$ Millions)

Table 38. Americas Short-acting EPO Drugs Revenue Market Share by Country (2018-2023)

Table 39. Americas Short-acting EPO Drugs Sales by Type (2018-2023) & (K Units)

Table 40. Americas Short-acting EPO Drugs Sales by Application (2018-2023) & (K Units)

Table 41. APAC Short-acting EPO Drugs Sales by Region (2018-2023) & (K Units)

Table 42. APAC Short-acting EPO Drugs Sales Market Share by Region (2018-2023)

Table 43. APAC Short-acting EPO Drugs Revenue by Region (2018-2023) & (\$ Millions)

Table 44. APAC Short-acting EPO Drugs Revenue Market Share by Region (2018-2023)

Table 45. APAC Short-acting EPO Drugs Sales by Type (2018-2023) & (K Units)

Table 46. APAC Short-acting EPO Drugs Sales by Application (2018-2023) & (K Units)

Table 47. Europe Short-acting EPO Drugs Sales by Country (2018-2023) & (K Units)

Table 48. Europe Short-acting EPO Drugs Sales Market Share by Country (2018-2023)

Table 49. Europe Short-acting EPO Drugs Revenue by Country (2018-2023) & (\$

Millions)

Table 50. Europe Short-acting EPO Drugs Revenue Market Share by Country (2018-2023)

Table 51. Europe Short-acting EPO Drugs Sales by Type (2018-2023) & (K Units)

Table 52. Europe Short-acting EPO Drugs Sales by Application (2018-2023) & (K Units)

Table 53. Middle East & Africa Short-acting EPO Drugs Sales by Country (2018-2023) & (K Units)

Table 54. Middle East & Africa Short-acting EPO Drugs Sales Market Share by Country (2018-2023)

Table 55. Middle East & Africa Short-acting EPO Drugs Revenue by Country (2018-2023) & (\$ Millions)

Table 56. Middle East & Africa Short-acting EPO Drugs Revenue Market Share by Country (2018-2023)

Table 57. Middle East & Africa Short-acting EPO Drugs Sales by Type (2018-2023) & (K Units)

Table 58. Middle East & Africa Short-acting EPO Drugs Sales by Application (2018-2023) & (K Units)

Table 59. Key Market Drivers & Growth Opportunities of Short-acting EPO Drugs

Table 60. Key Market Challenges & Risks of Short-acting EPO Drugs

Table 61. Key Industry Trends of Short-acting EPO Drugs

Table 62. Short-acting EPO Drugs Raw Material

Table 63. Key Suppliers of Raw Materials

Table 64. Short-acting EPO Drugs Distributors List

Table 65. Short-acting EPO Drugs Customer List

Table 66. Global Short-acting EPO Drugs Sales Forecast by Region (2024-2029) & (K Units)

Table 67. Global Short-acting EPO Drugs Revenue Forecast by Region (2024-2029) & (\$ millions)

Table 68. Americas Short-acting EPO Drugs Sales Forecast by Country (2024-2029) & (K Units)

Table 69. Americas Short-acting EPO Drugs Revenue Forecast by Country (2024-2029) & (\$ millions)

Table 70. APAC Short-acting EPO Drugs Sales Forecast by Region (2024-2029) & (K Units)

Table 71. APAC Short-acting EPO Drugs Revenue Forecast by Region (2024-2029) & (\$ millions)

Table 72. Europe Short-acting EPO Drugs Sales Forecast by Country (2024-2029) & (K Units)

Table 73. Europe Short-acting EPO Drugs Revenue Forecast by Country (2024-2029) &

(\$ millions)

Table 74. Middle East & Africa Short-acting EPO Drugs Sales Forecast by Country (2024-2029) & (K Units)

Table 75. Middle East & Africa Short-acting EPO Drugs Revenue Forecast by Country (2024-2029) & (\$ millions)

Table 76. Global Short-acting EPO Drugs Sales Forecast by Type (2024-2029) & (K Units)

Table 77. Global Short-acting EPO Drugs Revenue Forecast by Type (2024-2029) & (\$ Millions)

Table 78. Global Short-acting EPO Drugs Sales Forecast by Application (2024-2029) & (K Units)

Table 79. Global Short-acting EPO Drugs Revenue Forecast by Application (2024-2029) & (\$ Millions)

Table 80. Amgen Basic Information, Short-acting EPO Drugs Manufacturing Base, Sales Area and Its Competitors

Table 81. Amgen Short-acting EPO Drugs Product Portfolios and Specifications

Table 82. Amgen Short-acting EPO Drugs Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 83. Amgen Main Business

Table 84. Amgen Latest Developments

Table 85. Johnson & Johnson Basic Information, Short-acting EPO Drugs Manufacturing Base, Sales Area and Its Competitors

Table 86. Johnson & Johnson Short-acting EPO Drugs Product Portfolios and Specifications

Table 87. Johnson & Johnson Short-acting EPO Drugs Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 88. Johnson & Johnson Main Business

Table 89. Johnson & Johnson Latest Developments

Table 90. Roche Basic Information, Short-acting EPO Drugs Manufacturing Base, Sales Area and Its Competitors

Table 91. Roche Short-acting EPO Drugs Product Portfolios and Specifications

Table 92. Roche Short-acting EPO Drugs Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 93. Roche Main Business

Table 94. Roche Latest Developments

Table 95. Kyowa Kirin Basic Information, Short-acting EPO Drugs Manufacturing Base, Sales Area and Its Competitors

Table 96. Kyowa Kirin Short-acting EPO Drugs Product Portfolios and Specifications

Table 97. Kyowa Kirin Short-acting EPO Drugs Sales (K Units), Revenue (\$ Million),

Price (US\$/Unit) and Gross Margin (2018-2023)

Table 98. Kyowa Kirin Main Business

Table 99. Kyowa Kirin Latest Developments

Table 100. LG Chem Basic Information, Short-acting EPO Drugs Manufacturing Base, Sales Area and Its Competitors

Table 101. LG Chem Short-acting EPO Drugs Product Portfolios and Specifications

Table 102. LG Chem Short-acting EPO Drugs Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 103. LG Chem Main Business

Table 104. LG Chem Latest Developments

Table 105. Daewoong Pharmaceutical Basic Information, Short-acting EPO Drugs Manufacturing Base, Sales Area and Its Competitors

Table 106. Daewoong Pharmaceutical Short-acting EPO Drugs Product Portfolios and Specifications

Table 107. Daewoong Pharmaceutical Short-acting EPO Drugs Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 108. Daewoong Pharmaceutical Main Business

Table 109. Daewoong Pharmaceutical Latest Developments

Table 110. Wockhardt Basic Information, Short-acting EPO Drugs Manufacturing Base, Sales Area and Its Competitors

Table 111. Wockhardt Short-acting EPO Drugs Product Portfolios and Specifications

Table 112. Wockhardt Short-acting EPO Drugs Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 113. Wockhardt Main Business

Table 114. Wockhardt Latest Developments

Table 115. CJ Healthcare Basic Information, Short-acting EPO Drugs Manufacturing Base, Sales Area and Its Competitors

Table 116. CJ Healthcare Short-acting EPO Drugs Product Portfolios and Specifications

Table 117. CJ Healthcare Short-acting EPO Drugs Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 118. CJ Healthcare Main Business

Table 119. CJ Healthcare Latest Developments

Table 120. 3SBio Basic Information, Short-acting EPO Drugs Manufacturing Base, Sales Area and Its Competitors

Table 121. 3SBio Short-acting EPO Drugs Product Portfolios and Specifications

Table 122. 3SBio Short-acting EPO Drugs Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 123. 3SBio Main Business

Table 124. 3SBio Latest Developments

Table 125. Kexing Biopharm Basic Information, Short-acting EPO Drugs Manufacturing Base, Sales Area and Its Competitors

Table 126. Kexing Biopharm Short-acting EPO Drugs Product Portfolios and Specifications

Table 127. Kexing Biopharm Short-acting EPO Drugs Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 128. Kexing Biopharm Main Business

Table 129. Kexing Biopharm Latest Developments

Table 130. Harbin Pharmaceutical Group Basic Information, Short-acting EPO Drugs Manufacturing Base, Sales Area and Its Competitors

Table 131. Harbin Pharmaceutical Group Short-acting EPO Drugs Product Portfolios and Specifications

Table 132. Harbin Pharmaceutical Group Short-acting EPO Drugs Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 133. Harbin Pharmaceutical Group Main Business

Table 134. Harbin Pharmaceutical Group Latest Developments

Table 135. Beijing Four Rings Bio-Pharmaceutical Basic Information, Short-acting EPO Drugs Manufacturing Base, Sales Area and Its Competitors

Table 136. Beijing Four Rings Bio-Pharmaceutical Short-acting EPO Drugs Product Portfolios and Specifications

Table 137. Beijing Four Rings Bio-Pharmaceutical Short-acting EPO Drugs Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 138. Beijing Four Rings Bio-Pharmaceutical Main Business

Table 139. Beijing Four Rings Bio-Pharmaceutical Latest Developments

List Of Figures

LIST OF FIGURES

- Figure 1. Picture of Short-acting EPO Drugs
- Figure 2. Short-acting EPO Drugs Report Years Considered
- Figure 3. Research Objectives
- Figure 4. Research Methodology
- Figure 5. Research Process and Data Source
- Figure 6. Global Short-acting EPO Drugs Sales Growth Rate 2018-2029 (K Units)
- Figure 7. Global Short-acting EPO Drugs Revenue Growth Rate 2018-2029 (\$ Millions)
- Figure 8. Short-acting EPO Drugs Sales by Region (2018, 2022 & 2029) & (\$ Millions)
- Figure 9. Product Picture of Epoetin-alfa
- Figure 10. Product Picture of Epoetin-beta
- Figure 11. Product Picture of Darbepoetin-alfa
- Figure 12. Product Picture of Others
- Figure 13. Global Short-acting EPO Drugs Sales Market Share by Type in 2022
- Figure 14. Global Short-acting EPO Drugs Revenue Market Share by Type (2018-2023)
- Figure 15. Short-acting EPO Drugs Consumed in Anemia
- Figure 16. Global Short-acting EPO Drugs Market: Anemia (2018-2023) & (K Units)
- Figure 17. Short-acting EPO Drugs Consumed in Kidney Disorders
- Figure 18. Global Short-acting EPO Drugs Market: Kidney Disorders (2018-2023) & (K Units)
- Figure 19. Short-acting EPO Drugs Consumed in Others
- Figure 20. Global Short-acting EPO Drugs Market: Others (2018-2023) & (K Units)
- Figure 21. Global Short-acting EPO Drugs Sales Market Share by Application (2022)
- Figure 22. Global Short-acting EPO Drugs Revenue Market Share by Application in 2022
- Figure 23. Short-acting EPO Drugs Sales Market by Company in 2022 (K Units)
- Figure 24. Global Short-acting EPO Drugs Sales Market Share by Company in 2022
- Figure 25. Short-acting EPO Drugs Revenue Market by Company in 2022 (\$ Million)
- Figure 26. Global Short-acting EPO Drugs Revenue Market Share by Company in 2022
- Figure 27. Global Short-acting EPO Drugs Sales Market Share by Geographic Region (2018-2023)
- Figure 28. Global Short-acting EPO Drugs Revenue Market Share by Geographic Region in 2022
- Figure 29. Americas Short-acting EPO Drugs Sales 2018-2023 (K Units)
- Figure 30. Americas Short-acting EPO Drugs Revenue 2018-2023 (\$ Millions)
- Figure 31. APAC Short-acting EPO Drugs Sales 2018-2023 (K Units)

- Figure 32. APAC Short-acting EPO Drugs Revenue 2018-2023 (\$ Millions)
- Figure 33. Europe Short-acting EPO Drugs Sales 2018-2023 (K Units)
- Figure 34. Europe Short-acting EPO Drugs Revenue 2018-2023 (\$ Millions)
- Figure 35. Middle East & Africa Short-acting EPO Drugs Sales 2018-2023 (K Units)
- Figure 36. Middle East & Africa Short-acting EPO Drugs Revenue 2018-2023 (\$ Millions)
- Figure 37. Americas Short-acting EPO Drugs Sales Market Share by Country in 2022
- Figure 38. Americas Short-acting EPO Drugs Revenue Market Share by Country in 2022
- Figure 39. Americas Short-acting EPO Drugs Sales Market Share by Type (2018-2023)
- Figure 40. Americas Short-acting EPO Drugs Sales Market Share by Application (2018-2023)
- Figure 41. United States Short-acting EPO Drugs Revenue Growth 2018-2023 (\$ Millions)
- Figure 42. Canada Short-acting EPO Drugs Revenue Growth 2018-2023 (\$ Millions)
- Figure 43. Mexico Short-acting EPO Drugs Revenue Growth 2018-2023 (\$ Millions)
- Figure 44. Brazil Short-acting EPO Drugs Revenue Growth 2018-2023 (\$ Millions)
- Figure 45. APAC Short-acting EPO Drugs Sales Market Share by Region in 2022
- Figure 46. APAC Short-acting EPO Drugs Revenue Market Share by Regions in 2022
- Figure 47. APAC Short-acting EPO Drugs Sales Market Share by Type (2018-2023)
- Figure 48. APAC Short-acting EPO Drugs Sales Market Share by Application (2018-2023)
- Figure 49. China Short-acting EPO Drugs Revenue Growth 2018-2023 (\$ Millions)
- Figure 50. Japan Short-acting EPO Drugs Revenue Growth 2018-2023 (\$ Millions)
- Figure 51. South Korea Short-acting EPO Drugs Revenue Growth 2018-2023 (\$ Millions)
- Figure 52. Southeast Asia Short-acting EPO Drugs Revenue Growth 2018-2023 (\$ Millions)
- Figure 53. India Short-acting EPO Drugs Revenue Growth 2018-2023 (\$ Millions)
- Figure 54. Australia Short-acting EPO Drugs Revenue Growth 2018-2023 (\$ Millions)
- Figure 55. China Taiwan Short-acting EPO Drugs Revenue Growth 2018-2023 (\$ Millions)
- Figure 56. Europe Short-acting EPO Drugs Sales Market Share by Country in 2022
- Figure 57. Europe Short-acting EPO Drugs Revenue Market Share by Country in 2022
- Figure 58. Europe Short-acting EPO Drugs Sales Market Share by Type (2018-2023)
- Figure 59. Europe Short-acting EPO Drugs Sales Market Share by Application (2018-2023)
- Figure 60. Germany Short-acting EPO Drugs Revenue Growth 2018-2023 (\$ Millions)
- Figure 61. France Short-acting EPO Drugs Revenue Growth 2018-2023 (\$ Millions)

- Figure 62. UK Short-acting EPO Drugs Revenue Growth 2018-2023 (\$ Millions)
- Figure 63. Italy Short-acting EPO Drugs Revenue Growth 2018-2023 (\$ Millions)
- Figure 64. Russia Short-acting EPO Drugs Revenue Growth 2018-2023 (\$ Millions)
- Figure 65. Middle East & Africa Short-acting EPO Drugs Sales Market Share by Country in 2022
- Figure 66. Middle East & Africa Short-acting EPO Drugs Revenue Market Share by Country in 2022
- Figure 67. Middle East & Africa Short-acting EPO Drugs Sales Market Share by Type (2018-2023)
- Figure 68. Middle East & Africa Short-acting EPO Drugs Sales Market Share by Application (2018-2023)
- Figure 69. Egypt Short-acting EPO Drugs Revenue Growth 2018-2023 (\$ Millions)
- Figure 70. South Africa Short-acting EPO Drugs Revenue Growth 2018-2023 (\$ Millions)
- Figure 71. Israel Short-acting EPO Drugs Revenue Growth 2018-2023 (\$ Millions)
- Figure 72. Turkey Short-acting EPO Drugs Revenue Growth 2018-2023 (\$ Millions)
- Figure 73. GCC Country Short-acting EPO Drugs Revenue Growth 2018-2023 (\$ Millions)
- Figure 74. Manufacturing Cost Structure Analysis of Short-acting EPO Drugs in 2022
- Figure 75. Manufacturing Process Analysis of Short-acting EPO Drugs
- Figure 76. Industry Chain Structure of Short-acting EPO Drugs
- Figure 77. Channels of Distribution
- Figure 78. Global Short-acting EPO Drugs Sales Market Forecast by Region (2024-2029)
- Figure 79. Global Short-acting EPO Drugs Revenue Market Share Forecast by Region (2024-2029)
- Figure 80. Global Short-acting EPO Drugs Sales Market Share Forecast by Type (2024-2029)
- Figure 81. Global Short-acting EPO Drugs Revenue Market Share Forecast by Type (2024-2029)
- Figure 82. Global Short-acting EPO Drugs Sales Market Share Forecast by Application (2024-2029)
- Figure 83. Global Short-acting EPO Drugs Revenue Market Share Forecast by Application (2024-2029)

I would like to order

Product name: Global Short-acting EPO Drugs Market Growth 2023-2029

Product link: <https://marketpublishers.com/r/GE17519CCE93EN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GE17519CCE93EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970